AT283865T - Peptide analogs having an inhibitory effect on hepatitis c - Google Patents

Peptide analogs having an inhibitory effect on hepatitis c

Info

Publication number
AT283865T
AT283865T AT98939997T AT98939997T AT283865T AT 283865 T AT283865 T AT 283865T AT 98939997 T AT98939997 T AT 98939997T AT 98939997 T AT98939997 T AT 98939997T AT 283865 T AT283865 T AT 283865T
Authority
AT
Austria
Prior art keywords
hepatitis
inhibitory effect
peptide analogs
analogs
peptide
Prior art date
Application number
AT98939997T
Other languages
German (de)
Inventor
Montse Llinas-Brunet
Murray Douglas Bailey
Teddy Halmos
Marc-Andre Poupart
Youla Tsantrizos
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5524797P priority Critical
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Priority to PCT/CA1998/000764 priority patent/WO1999007734A2/en
Publication of AT283865T publication Critical patent/AT283865T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT98939997T 1997-08-11 1998-08-10 Peptide analogs having an inhibitory effect on hepatitis c AT283865T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US5524797P true 1997-08-11 1997-08-11
PCT/CA1998/000764 WO1999007734A2 (en) 1997-08-11 1998-08-10 Hepatitis c inhibitor peptide analogues

Publications (1)

Publication Number Publication Date
AT283865T true AT283865T (en) 2004-12-15

Family

ID=21996648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939997T AT283865T (en) 1997-08-11 1998-08-10 Peptide analogs having an inhibitory effect on hepatitis c

Country Status (13)

Country Link
US (1) US6143715A (en)
EP (1) EP1012180B1 (en)
JP (1) JP4452401B2 (en)
AT (1) AT283865T (en)
AU (1) AU757072B2 (en)
CA (1) CA2294562C (en)
DE (1) DE69827956T2 (en)
ES (1) ES2234144T3 (en)
HU (1) HU0100100A3 (en)
IL (1) IL134233D0 (en)
NZ (1) NZ503263A (en)
PT (1) PT1012180E (en)
WO (1) WO1999007734A2 (en)

Families Citing this family (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN183120B (en) 1996-10-18 1999-09-11 Vertex Pharma Process for preparing inhibitors of serine proteases particularly hepatitis C virus ns3 proteases
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
AT346035T (en) * 1998-03-31 2006-12-15 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
GB9809664D0 (en) * 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ID30459A (en) * 1999-04-06 2001-12-06 Boehringer Ingelheim Ca Ltd Macrocyclic peptides that are active against hepatitis C virus
CA2376961A1 (en) * 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
JP2003516732A (en) * 1999-11-24 2003-05-20 カイロン コーポレイション Novel hcv non-structural polypeptides
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
AR029903A1 (en) * 2000-04-05 2003-07-23 Schering Corp macrocyclic inhibitors NS3-serine protease, the Hepatitis C virus, comprising portions p2 n-cyclic, pharmaceutical compositions and use of the same for the manufacture of a medicament
CN101580536A (en) * 2000-04-19 2009-11-18 先灵公司 Macrocyclic ns-3 serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
MY164523A (en) 2000-05-23 2017-12-29 Idenix (Cayman) Ltd Methods and compositions for treating hepatitis c virus
CZ301182B6 (en) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SI1385870T1 (en) * 2000-07-21 2010-08-31 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (en) 2000-07-21 2003-07-16 Dendreon Corp New peptides as inhibitors of NS3-serine protease of hepatitis C virus
HU0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli Peptidomimetic protease inhibitors ref. x-14912m
DK2251015T3 (en) 2000-10-18 2013-05-13 Gilead Pharmasset Llc Modified nucleotides to treat viral infections and abnormal cell proliferation
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
MXPA03006514A (en) 2001-01-22 2004-12-02 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase.
CN100402549C (en) 2001-07-11 2008-07-16 沃泰克斯药物股份有限公司 Bridged bicyclic serine protease inhibitors
AT539744T (en) 2001-10-24 2012-01-15 Vertex Pharma Inhibitors of serine protease, particularly, Hepatitis C virus NS3-NS4A protease, ring system with a condensed
US20050009873A1 (en) * 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
US20030176689A1 (en) * 2001-12-14 2003-09-18 Michael Joyce Inhibitors of hepatitis C virus protease
KR20040077767A (en) 2002-01-23 2004-09-06 쉐링 코포레이션 Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatitis C virus infection
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
MXPA04009938A (en) 2002-04-11 2004-12-13 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease.
MY140680A (en) 2002-05-20 2010-01-15 Squibb Bristol Myers Co Hepatitis c virus inhibitors
US7041698B2 (en) 2002-05-20 2006-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1505945B1 (en) 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
PL211889B1 (en) 2002-05-20 2012-07-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
KR20050048544A (en) 2002-06-28 2005-05-24 이데닉스 (케이만) 리미티드 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
PL377342A1 (en) 2002-11-15 2006-01-23 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
ES2297424T3 (en) * 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Inhibitor compounds hepatitis c.
JP4958158B2 (en) 2003-05-30 2012-06-20 ギリアド ファーマセット エルエルシー Modified fluorinated nucleoside analogues
KR20060084845A (en) 2003-07-25 2006-07-25 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄 (쎄엔알에스) Purin nucleoside analogues for treating flaviviridae including hepatitis c
WO2005021584A2 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06003141A (en) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Macrocyclic peptides active against the hepatitis c virus.
AU2004276281A1 (en) 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
EP2361925A1 (en) 2003-10-10 2011-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
JP4890254B2 (en) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated HCVNS3-NS4A protease resistant mutant
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2546290A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
US7671032B2 (en) 2004-01-30 2010-03-02 Medivir Ab HCV NS-3 serine protease inhibitors
CA2554999A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN103304541A (en) 2004-02-20 2013-09-18 贝林格尔.英格海姆国际有限公司 Viral polymerase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
EP2206715A1 (en) 2004-02-24 2010-07-14 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor
US7192957B2 (en) 2004-02-27 2007-03-20 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
JP2007525512A (en) 2004-02-27 2007-09-06 シェーリング コーポレイションSchering Corporation As the 3,4-inhibitors of the hepatitis C virus ns3 serine protease (cyclopentyl) - condensation proline compound
KR20060124729A (en) 2004-02-27 2006-12-05 쉐링 코포레이션 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
PT1730110E (en) 2004-02-27 2010-09-14 Schering Corp Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200536528A (en) 2004-02-27 2005-11-16 Schering Corp Novel inhibitors of hepatitis C virus NS3 protease
MXPA06013404A (en) 2004-05-20 2007-01-23 Schering Corp Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease.
JP5055564B2 (en) 2004-06-15 2012-10-24 アイシス ファーマシューティカルズ, インコーポレーテッド C-purine nucleoside analogues as inhibitors of RNA-dependent RNA viral polymerase
CN1972696B (en) 2004-06-24 2010-08-11 默沙东公司 Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogs of dipeptide inhibitors of hepatitis c
JP4914355B2 (en) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C inhibitor peptide analog
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008511633A (en) 2004-08-27 2008-04-17 シェーリング コーポレイションSchering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus ns3 serine proteases
EP3109244B1 (en) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
BRPI0516825A (en) 2004-10-01 2008-09-23 Vertex Pharma inhibition of NS3-NS4A protease of hepatitis C virus (HCV)
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4705164B2 (en) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Hcvns3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2546246A3 (en) 2005-05-13 2013-04-24 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
CA2610167A1 (en) 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130628A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Combination of hcv protease inhibitors with a surfactant
KR20080033274A (en) 2005-06-17 2008-04-16 노파르티스 아게 Use of sanglifehrin in hcv
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
EP1924594A2 (en) 2005-07-25 2008-05-28 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
PE02112007A1 (en) 2005-07-29 2007-05-12 Medivir Ab macrocyclic compounds as inhibitors of hepatitis C virus
AT496908T (en) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Macrocyclic inhibitors of the Hepatitis C virus
AR055105A1 (en) 2005-07-29 2007-08-08 Tibotec Pharm Ltd macrocyclic inhibitors of Hepatitis C virus
MY141245A (en) 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
PE02102007A1 (en) 2005-07-29 2007-04-16 Tibotec Pharm Ltd macrocyclic compounds as inhibitors of hepatitis C virus
US8012939B2 (en) 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
ME01318B (en) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
WO2007016441A1 (en) 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1915054A4 (en) 2005-08-09 2010-09-01 Merck Sharp & Dohme Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
JP5015154B2 (en) 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
PT2194043E (en) 2005-08-19 2014-03-04 Vertex Pharma Processes
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma Compounds activity inhibitors of serine NS3-NS4A protease of Hepatitis C virus
DK1999129T3 (en) 2005-10-11 2011-02-07 Intermune Inc Compounds and methods for inhibiting the replication of hepatitis C virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2006315438A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
TW200800265A (en) * 2006-02-09 2008-01-01 Schering Corp Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
CN102614490A (en) 2006-02-27 2012-08-01 弗特克斯药品有限公司 Co-crystals having VX-950 and pharmaceutical compositions comprising the same
JP2009531315A (en) * 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Deuterated c hepatitis protease inhibitor
EP1998759A2 (en) * 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
KR101069051B1 (en) 2006-05-23 2011-09-29 아이알엠 엘엘씨 Compounds and compositions as channel activating protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CN101506167A (en) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 Viral polymerase inhibitors
JP5345941B2 (en) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. HCV NS3 protease inhibitor
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP2010507656A (en) 2006-10-24 2010-03-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Hcvns3 protease inhibitors
CA2667032A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
RU2468029C2 (en) 2006-10-27 2012-11-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти С.П.А. Hcv ns3 ptotease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2559691A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010512317A (en) * 2006-12-07 2010-04-22 シェーリング コーポレイションSchering Corporation pH-sensitive matrix formulation
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
BRPI0720625A2 (en) 2006-12-22 2014-03-25 Schering Corp 4,5-ring indol derivatives and methods of use
CN101641349A (en) 2007-02-08 2010-02-03 泰博特克药品有限公司;美迪维尔公司 Pyrimidine substituted macrocyclic HCV inhibitors
MX2009008518A (en) 2007-02-09 2009-08-20 Irm Llc Compounds and compositions as channel activating protease inhibitors.
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
AP200904960A0 (en) 2007-02-27 2009-08-31 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
US20100104534A1 (en) * 2007-03-23 2010-04-29 Srikanth Venkatraman Hydrazido-peptides as inhibitors of hcv ns3-protease
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
TW200914013A (en) 2007-06-29 2009-04-01 Gilead Sciences Inc Antiviral compounds
CN101790524B (en) 2007-06-29 2014-07-16 吉里德科学公司 Antiviral compounds
JP2010533698A (en) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Macrocyclic indole derivatives for the treatment of hepatitis C infection
JP5433573B2 (en) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Macrocyclic compounds as antiviral agents
JP2010535156A (en) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
KR20100065167A (en) 2007-08-29 2010-06-15 쉐링 코포레이션 2,3-substituted azaindole derivatives for treating viral infections
US8143305B2 (en) 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
EP2408761B1 (en) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
CN101835774B (en) 2007-08-30 2014-09-17 弗特克斯药品有限公司 Co-crystals and pharmaceutical compositions comprising the same
JP2012520884A (en) 2009-03-18 2012-09-10 アイガー バイオファーマシューティカルズ インコーポレイテッド Methods and compositions for treating flaviviridae viral infections
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
CN102099351A (en) 2007-11-16 2011-06-15 先灵公司 3-heterocyclic substituted indole derivatives and methods of use thereof
US8377928B2 (en) 2007-11-16 2013-02-19 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
JP5529036B2 (en) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド Fluorinated tripeptide HCV serine protease inhibitor
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2490272C2 (en) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Macrocyclic serine protease inhibitors
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102159579B (en) 2008-06-13 2015-03-25 默沙东公司 Tricyclic indole derivatives and methods of use thereof
CN102177172A (en) 2008-07-02 2011-09-07 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
PE02122011A1 (en) 2008-07-22 2011-04-10 Merck Sharp & Dohme (1aR, 5S, 8S, 10R, 22aR) -5-tert-butyl-N - {(1R, 2S) -1 - {[(cyclopropylsulfonyl) amino] carbonyl} -2-vinylcyclopropyl} -14-methoxy-3, 6-DIOXO-1, 1a, 3, 4, 5, 6, 9, 10, 18, 19, 20, 21, 22, 22a-tetradecahydro-8H-7, 10-METANOCICLOPROPA [18, 19] [1, 10 , 3, 6] DIOXADIAZACICLONONADECINO [11, 12-b] quinoxaline-8-carboxamide as HCV protease inhibitor NS3
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8541434B2 (en) 2008-08-20 2013-09-24 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282572B2 (en) 2008-08-20 2014-09-11 Merck Sharp & Dohme Corp. Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
KR20110098779A (en) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Inhibitors of hcv ns5a
MX2011005898A (en) 2008-12-03 2011-09-27 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a.
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2009002207A1 (en) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compounds derived from 3-hydroxy-5- (9H-purin-9-yl) tetrahydrofuran-2-yl, replication inhibitor of viral RNA-dependent RNA; pharmaceutical composition; use for the treatment of hepatitis c.
CL2009002206A1 (en) 2008-12-23 2011-08-26 Gilead Pharmasset Llc pyrrolo derivatives - (2,3-d] pyrimidin-7 (6H) -tetrahydrofuran-2-yl phosphonamidate, pharmaceutical composition, and its use in treating viral diseases.
RU2011127080A (en) 2009-01-07 2013-02-20 Сайнексис, Инк. Cyclosporin derivative for use in the treatment of hepatitis c and hiv virus infection
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 Gilead Pharmasset Llc Amides nucleoside phosphorylase
JP2012528195A (en) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Antibacterial compounds composed of three linked aryl moieties for treating diseases such as hepatitis C
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
AR077712A1 (en) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
EP2477980B1 (en) 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
JP2013512247A (en) 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 5-Alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
KR20120130173A (en) 2009-12-24 2012-11-29 버텍스 파마슈티칼스 인코포레이티드 Analogues for treatment or prevention of flavivirus infections
JP5833022B2 (en) 2010-01-27 2015-12-16 エービー・ファーマ・リミテッド Polyheterocyclic compounds as hepatitis C virus inhibitors
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550267A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (en) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Analogs for treating or preventing flavivirus infection
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
CN102917585A (en) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (en) 2010-06-28 2012-10-10 Vertex Pharma Thiophene derivatives, methods for their preparation and their use in the treatment or prevention of flavivirus infections
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AR082619A1 (en) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibitors of Hepatitis C virus
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
US8648037B2 (en) 2010-09-21 2014-02-11 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived HCV serine protease inhibitors
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
MX2013003945A (en) 2010-10-08 2013-06-05 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors.
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
RU2014102102A (en) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. COMPOSITION AND COMBINED DRUG INTERFERON-a5 WITH INTERFERON-a2 AND METHOD OF TREATMENT OF CHRONIC HEPATITIS C
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
AR087346A1 (en) 2011-07-26 2014-03-19 Vertex Pharma Formulations thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
TW201329096A (en) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2766365A1 (en) 2011-10-10 2014-08-20 F.Hoffmann-La Roche Ag Antiviral compounds
AR089650A1 (en) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc 3,5-cyclic phosphate compounds substituted purine nucleotide and pharmaceutical compositions for treating viral infections
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
SG11201402899TA (en) 2011-12-06 2014-07-30 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
BR112014013972A8 (en) 2011-12-16 2017-06-13 Hoffmann La Roche hcv inhibitors nssa
US9708357B2 (en) 2011-12-20 2017-07-18 Riboscience, LLC 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2013092481A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
JP6092261B2 (en) 2012-02-24 2017-03-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Antiviral compounds
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
MD20140134A2 (en) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid compounds for the treatment of liver diseases
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC. 3',5'-cyclic phosphate prodrugs for hcv infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
US20140099283A1 (en) 2012-10-08 2014-04-10 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
ES2613766T3 (en) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Carbamate derivatives of hexadecahydrocyclopropa (e) pyrrolo (1,2-a) (1,4) diazacyclopentadecinyl substituted with 9-methyl as inhibitors of non-structural protease 3 (NS3) for the treatment of hepatitis C virus infections
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP2948440B1 (en) 2013-01-23 2017-04-12 F.Hoffmann-La Roche Ag Antiviral triazole derivatives
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
RU2015136256A (en) 2013-03-05 2017-04-10 Ф. Хоффманн-Ля Рош Аг Anti-viral compounds
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
BR112015028764A2 (en) 2013-05-16 2017-07-25 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
KR20160039154A (en) 2013-05-16 2016-04-08 리보사이언스 엘엘씨 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US20180162898A1 (en) 2013-12-18 2018-06-14 Idenix Pharmaceuticals Llc 4'-or nucleosides for the treatment of hcv
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
WO2018036957A1 (en) * 2016-08-23 2018-03-01 F. Hoffmann-La Roche Ag New trifluoromethylpropanamide derivatives as htra1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3481913D1 (en) * 1983-04-27 1990-05-17 Ici America Inc Proline derivatives.
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
IN183120B (en) * 1996-10-18 1999-09-11 Vertex Pharma Process for preparing inhibitors of serine proteases particularly hepatitis C virus ns3 proteases
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) * 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) * 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors

Also Published As

Publication number Publication date
HU0100100A2 (en) 2001-11-28
CA2294562A1 (en) 1999-02-18
HU0100100A3 (en) 2001-12-28
IL134233D0 (en) 2001-04-30
AU8846698A (en) 1999-03-01
JP2001512744A (en) 2001-08-28
WO1999007734A2 (en) 1999-02-18
DE69827956D1 (en) 2005-01-05
DE69827956T2 (en) 2005-04-14
EP1012180B1 (en) 2004-12-01
US6143715A (en) 2000-11-07
CA2294562C (en) 2005-07-26
NZ503263A (en) 2002-10-25
AU757072B2 (en) 2003-01-30
WO1999007734A3 (en) 1999-05-20
EP1012180A2 (en) 2000-06-28
JP4452401B2 (en) 2010-04-21
ES2234144T3 (en) 2005-06-16
PT1012180E (en) 2005-04-29

Similar Documents

Publication Publication Date Title
DE69430196T2 (en) donor
DE69730918D1 (en) Anti-fog element
DE69402202D1 (en) An electrosurgical generator
DE69721624D1 (en) injection
AT168081T (en) Electrically operated park-brake system
ITTO970339A1 (en) Distributor
DE69230824D1 (en) New tetrapeptide derivatives
DE69303628D1 (en) Piezoelectric, electronic switch
ATA901789A (en) somatostatin peptide
DE69636026D1 (en) Plasma-assisted bipolar electrosurgical system
DE69634875D1 (en) promoter sequences Kälteindusierbare
NO982098L (en) peptides
DE69601539T2 (en) An electrosurgical cutting-koagulationsapparat
DE69427762T2 (en) Ablation on intermediates
AT288134T (en) arrangements electroluminescent
DE69831177D1 (en) Antistatic compositions on the basis of polyamide
DE69738612D1 (en) sputtering Target
NO312516B1 (en) Peptide nucleic acids
DE69431485T2 (en) peptide nucleic acids double
DE9390075U1 (en) A bipolar electrosurgical cutting-handle
DE69033425T2 (en) HCV isolate J-1
DE69836969D1 (en) switching arrangement
DE69431164D1 (en) Opposing oligonucleotides having an inhibitory effect on tumor formation
DE69435118D1 (en) Purified compositions from Newcastle disease virus
DE69840642D1 (en) Soccer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012180

Country of ref document: EP